which is the industry’s largest antibody Fab library to date, uses a unique concept for the in vitro generation of highly specific and fully human antibodies.
Ylanthia® goes one step further than all current antibody technologies. The technologies currently available make the successful development of therapeutic antibodies difficult in two respects. On the one hand, many antibody programs fail in later development due to inadequate biophysical properties, which classify the active ingredient as "undevelopable". If an antibody cannot be produced on a larger scale or if other properties adversely affect its handling, the chances of successful commercialization decrease. On the other hand, earlier generations of technology fail to deliver antibodies against all possible targets (epitopes) of disease-relevant target molecules. This can lead to highly promising target molecules being wrongly rejected. A lack of structural diversity, i.e. diversity, in the generation of antibodies means that not all possibilities to bind to a promising target molecule are exhausted and its role in the course of the disease is underestimated. The Ylanthia® technology has been specifically designed to remove these hurdles.
The antibody library has all the necessary prerequisites for selecting antibodies against all possible starting points of disease-relevant target molecules due to the structural range and diversity of the library. If one can succeed in exhausting all of the possibilities for binding promising target molecules, this can result in unique product opportunities and compound candidates that can intervene at the crucial points in a disease process.